Among 124 genotype 1b-infected chronic hepatitis C patients recruited , 116 eligible patients were allocated randomly to two study arms ; they received 12 weeks of telaprevir/peg-IFN/RBV , followed by 12 weeks of peg-IFN/RBV with or without 24 weeks of fluvastatin ( fluvastatin group and control group , respectively ) .